GAITHERSBURG, Md., Oct. 13, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) announced today that Barclay A. “Buck” Phillips has submitted his resignation as Senior Vice President, Chief Financial Officer (CFO) and Treasurer, to pursue an expanded opportunity in the industry. Mr. Phillips will step down effective November 10, 2017, and will provide financial, accounting and transition services as a consultant to Novavax until December 31, 2017. Mr. Erck will act as the interim CFO pending completion of a search for a new Chief Financial Officer.
“Buck has been instrumental in a number of significant Novavax accomplishments, and we thank him for all his contributions over the last four years. We wish him all the best in his new endeavors,” said Stanley C. Erck, President and CEO of Novavax.
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
Investor Relations Novavax, Inc. Andrea N. Flynn, Ph.D. Director, Investor & Media Relations firstname.lastname@example.org 240-268-2000
Source: Novavax, Inc.
and functionality of our services, and analyze the use of our products and services. By clicking
‘Accept’ you are indicating your
consent for us to place these cookies. For more information, please read our Privacy
Policy or manage your cookie settings.